Houston hospital performs first fully robotic heart transplant in the U.S.

robotic surgery

Dr. Kenneth Liao and a team at Baylor St. Luke’s Medical Center used a surgical robot to implant a new heart in a 45-year-old male patient. Photo courtesy Baylor College of Medicine.

A team at Baylor St. Luke’s Medical Center, led by Dr. Kenneth Liao, successfully performed the first fully robotic heart transplant in the United States earlier this year, the Houston hospital recently shared.

Liao, a professor and chief of cardiothoracic transplantation and circulatory support at Baylor College of Medicine and chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke’s Medical Center, used a surgical robot to implant a new heart in a 45-year-old male patient through preperitoneal space in the abdomen by making small incisions.

The robotic technology allowed the medical team to avoid opening the chest and breaking the breast bone, which reduces the risk of infection, blood transfusions and excessive bleeding. It also leads to an easier recovery, according to Liao.

"Opening the chest and spreading the breastbone can affect wound healing and delay rehabilitation and prolong the patient's recovery, especially in heart transplant patients who take immunosuppressants," Liao said in a news release. "With the robotic approach, we preserve the integrity of the chest wall, which reduces the risk of infection and helps with early mobility, respiratory function and overall recovery."

The patient received the heart transplant in March, after spending about four months in the hospital due to advanced heart failure. According to Baylor, he was discharged home after recovering from the surgery in the hospital for a month without complications.

"This transplant shows what is possible when innovation and surgical experience come together to improve patient care," Liao added in the release. "Our goal is to offer patients the safest, most effective and least invasive procedures, and robotic technology allows us to do that in extraordinary ways."

From Your Site Articles
BiVACOR and The Texas Heart Institute have celebrated a major milestone in the future of heart health. Photo courtesy of BiVACOR

Houston medical device startup implants artificial heart in first human patient

big win

Heart health tech company BiVACOR and The Texas Heart Institute announced that they successfully implanted the company's first Total Artificial Heart in a human at Baylor St. Luke’s Medical Center in the TMC.

The milestone is part of an FDA-approved early feasibility study that will test the safety and performance of the TAH device, which is based on a magnetically levitated rotor that takes over functions of a failing heart while a patient is awaiting a heart transplant, according to a statement from the organizations.

The "bridge-to-transplant" device could support an active adult male, as well as many women and children suffering from severe biventricular heart failure or univentricular heart failure.

"With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant,” Dr. Joseph Rogers, president and CEO of THI and national principal investigator on the research, says in a statement. “We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.”

BiVACOR received approval from the FDA for the early feasibility study in late 2023 and has four other patients enrolled in the study. At the time the study was approved, 10 hospitals were enrolled as possible sites.

“I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute ... our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial,” Daniel Timms, PhD, founder and CTO of BiVACOR, adds.

About 100,000 patients suffering from severe heart failure could benefit from BiVACOR’s artificial heart, the company says. Globally, only about 6,000 heart transplants are performed each year, while 26 million people worldwide are affected by heart failure.

BiVACOR was founded in 2008 and maintains its headquarters in Houston, along with offices in Huntington Beach, California, and Brisbane, Australia.

To date, the company has raised nearly $50.8 million, according to CB Insights. The company raised $18 million in 2023, and $22 million in 2021.

Earlier this year, BiVACOR named a new CEO in Jim Dillon, a longtime executive in the medical device sector.

Last summer, Rogers joined the Houston Innovators Podcast to share his excitement with THI's innovations.


Thomas Vassiliades, CEO of BiVACOR, joins the Houston Innovators Podcast. Photo courtesy of BiVACOR

How this Houston-headquartered company is innovating the future of heart replacement

HOUSTON INNOVATORS PODCAST EPISODE 183

Heart disease is one of the most common causes of death in the United States — one in five deaths, according to the CDC. But there's not a long-term solutions for patients — even for those lucky enough to have a successful heart transplant. But a Houston-headquartered medical device company is working on one.

BiVACOR has created a technology that, theoretically, could completely replace a patient's heart and last them the rest of their lives.

"The design is critical," says Thomas Vassiliades, CEO of BiVACOR, on the Houston Innovators Podcast. He joined the organization last year after spending 20 years of a heart surgeon, then transitioning to medical device development over a decade ago.

Vassiliades explains the industry's challenges on the show, saying that there's no comprehensive, lasting replacement to the human heart on the market. While some treatments — like transplants and medical devices that partially replace the heart's capabilities — exist, nothing that completely replaces the heart lasts longer than 10 to 12 years.

"The BiVACOR system is based on magnetic levitation," Vassiliades says about the technology. "Our pump is just one moving impeller that sits in the middle of the housing where the blood is. Imagine an artificial heart — the container that has your blood — and the device spinning in the inside — basically a wheel spinning your blood to the rest of your body.

"The device is suspended by magnets — it's not touching anything," he continues. "So, theoretically, the device has no wear and can last as long as the patient can possibly live. That's new to the field."

Daniel Timms, BiVACOR's founder and CTO, knew there had to be a better, more permanent solution and has been working on the technology since he was a postdoctoral student at Queensland University of Technology in Australia. His work took him to Houston's Texas Heart Institute, the "center of the universe when it comes to blood pumps," says Vassiliades.

The company recently raised $18 million in funding to support its growing team and continued growth. BiVACOR is a Class 3 medical device — the most rigorously regulated type of device, so the funding raised will support the company as it continues to meet the FDA's requirements and proceeds into implantation and clinical trials.

While headquartered in Houston and has close ties to THI, most of BiVACOR's team works out of Huntington Beach, California, just 30 minutes away from its manufacturing partner — something that has been critical for the design phase. Other employees work in Europe and Australia, which has resulted in government grant funding. Each market the company works in has a strategic purpose — and Houston's role is testing.

"We're going to be training all our clinical sites in Houston, and we're going to continue to do ongoing testing," he says. "We're very comfortable with the design of the device, ... but there's always more. And we have a long-term plan to iterate on the device to make it even better."

Vassiliades shares more of the challenges he's facing as he commercializes BiVACOR's technology on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice University professor earns $550k NSF award for wearable imaging tech​

science supported

Another Houston scientist has won one of the highly competitive National Science Foundation (NSF) CAREER Awards.

Lei Li, an assistant professor of electrical and computer engineering at Rice University, has received a $550,000, five-year grant to develop wearable, hospital-grade medical imaging technology capable of visualizing deep tissue function in real-time, according to the NSF. The CAREER grants are given to "early career faculty members who demonstrate the potential to serve as academic models and leaders in research and education."

“This is about giving people access to powerful diagnostic tools that were once confined to hospitals,” Li said in a news release from Rice. “If we can make imaging affordable, wearable and continuous, we can catch disease earlier and treat it more effectively.”

Li’s research focuses on photoacoustic imaging, which merges light and sound to produce high-resolution images of structures deep inside the body. It relies on pulses of laser light that are absorbed by tissue, leading to a rapid temperature rise. During this process, the heat causes the tissue to expand by a fraction, generating ultrasound waves that travel back to the surface and are detected and converted into an image. The process is known to yield more detailed images without dyes or contrast agents used in some traditional ultrasounds.

However, current photoacoustic systems tend to use a variety of sensors, making them bulky, expensive and impractical. Li and his team are taking a different approach.

Instead of using hundreds of separate sensors, Li and his researchers are developing a method that allows a single sensor to capture the same information via a specially designed encoder. The encoder assigns a unique spatiotemporal signature to each incoming sound wave. A reconstruction algorithm then interprets and decodes the signals.

These advances have the potential to lower the size, cost and power consumption of imaging systems. The researchers believe the device could be used in telemedicine, remote diagnostics and real-time disease monitoring. Li’s lab will also collaborate with clinicians to explore how the miniaturized technology could help monitor cancer treatment and other conditions.

“Reducing the number of detection channels from hundreds to one could shrink these devices from bench-top systems into compact, energy-efficient wearables,” Li said in the release. “That opens the door to continuous health monitoring in daily life—not just in hospitals.”

Amanda Marciel, the William Marsh Rice Trustee Chair of chemical and biomolecular engineering and an assistant professor at Rice, received an NSF CAREER Award last year. Read more here.

Houston Spaceport launches $12M expansion for leading space tech co.

to the moon

Houston will get one step closer to the moon, as the Houston Spaceport at Ellington Airport (EFD) has announced an expansion of the lease for Intuitive Machines, the Houston space tech leader dedicated to furthering lunar exploration.

On July 15, the City of Houston announced passage of Amendment 1, which would add three acres of commercial space for Intuitive Machines at the spaceport and a $12 million infrastructure expansion. Approved by the city council and Mayor John Whitmire, the expansion will include new production, testing and support facilities. The amendment extends the current lease for Intuitive Machines from 20 years to 25 years.

"I want to shout out to Intuitive Machines about everything they’re doing at the Houston Spaceport. It’s exciting to see them expand. We’re starting to reach a critical mass out there — more and more aerospace companies want to be at the Spaceport because that’s where innovation is happening,” said Fred Flinkinger, who represents District E on the Houston City Council. “It’s a great sign of momentum, and we’re proud to have them here in Houston."

Intuitive Machines was the first commercial tenant for the Houston Spaceport when it moved into the facility in August 2016. Founded by Stephen Altemus, Kam Ghaffarian, and Tim Crain in 2013, the company holds three contracts with the National Aeronautics and Space Administration (NASA) to deliver payloads to the lunar surface. In 2023, the company opened its doors in Houston with a 105,572-square-foot Lunar Production and Operations Center that contains research and development labs, clean rooms, mission control centers, and a spacecraft assembly floor.


Intuitive Machines landed Odysseus on the moon in February 2024, the first privately owned soft lunar landing ever and the first soft landing since 1972.

The Houston Spaceport is owned and operated by the City of Houston and Houston Airports, who have an eye of keeping the city a prime name in space exploration. As "Houston" was the first word spoken on the moon when Apollo 11 landed in 1969, lunar exploration in particular has a soft place in the heart of the metropolis formerly known as Space City.

“This agreement reinforces Houston’s leadership in space innovation,” said Jim Szczesniak, director of aviation for Houston Airports. “We’re building infrastructure and supporting the next era of lunar and deep space exploration, right here at Houston Spaceport. This partnership represents the forward-thinking development that fuels job creation and drives long-term economic growth.”

Houston hardtech accelerator names 8 scientists to 2025 cohort

ready, set, activate

National hardtech-focused organization Activate has named its 2025 cohort of scientists, which includes new members to Activate Houston.

The Houston hub was introduced last year, and joins others in Boston, New York, and Berkley, California—where Activate is headquartered. The organization also offers a virtual and remote cohort, known as Activate Anywhere. Collectively, the 2025 Activate Fellowship consists of 47 scientists and engineers from nine U.S. states.

This year's cohort comprises subject matter experts across various fields, including quantum, robotics, biology, agriculture, energy and direct air capture.

Activate aims to support scientists at "the outset of their entrepreneurial journey." It partners with U.S.-based funders and research institutions to support its fellows in developing high-impact technology. The fellows receive a living stipend, connections from Activate's robust network of mentors and access to a curriculum specific to the program for two years.

“Science entrepreneurship is the origin story of tomorrow’s industries,” Cyrus Wadia, CEO of Activate, said in an announcement. “The U.S. has long been a world center for science leadership and technological advancement. When it comes to solving the world’s biggest challenges, hard-tech innovation is how we unlock the best solutions. From infrastructure to energy to agriculture, these Activate Fellows are the bold thinkers who are building the next generation of science-focused companies to lead us into the future.”

The Houston fellows selected for the 2025 class include:

  • Jonathan Bessette, founder and CEO of KIRA, which uses its adaptive electrodialysis system to treat diverse water sources and reduce CO2 emissions
  • Victoria Coll Araoz, co-founder and chief science officer of Florida-based SEMION, an agricultural technology company developing pest control strategies by restoring crops' natural defenses
  • Eugene Chung, co-founder and CEO of Lift Biolabs, a biomanufacturing company developing low-cost, nanobubble-based purification reagents. Chung is completing his Ph.D. in bioengineering at Rice University.
  • Isaac Ju, co-founder of EarthFlow AI, which has developed an AI-powered platform for subsurface modeling, enabling the rapid scaling of carbon storage, geothermal energy and lithium extraction
  • Junho Lee, principal geotechnical engineer of Houston-based Deep Anchor Solutions, a startup developing innovative anchoring systems for floating renewables and offshore infrastructure
  • Sotiria (Iria) Mostrou, principal inventor at Houston-based Biosimo Chemicals, a chemical engineering startup that develops and operates processes to produce bio-based platform chemicals
  • Becca Segel, CEO and founder of Pittsburgh-based FlowCellutions, which prevents power outages for critical infrastructure such as hospitals, data centers and the grid through predictive battery diagnostics
  • Joshua Yang, CEO and co‑founder of Cambridge, Massachusetts-based Brightlight Photonics, which develops chip-scale titanium: sapphire lasers to bring cost-effective, lab-grade performance to quantum technologies, diagnostics and advanced manufacturing

The program, led locally by Houston Managing Director Jeremy Pitts, has supported 296 Activate fellows since the organization was founded in 2015. Members have gone on to raise roughly $4 billion in follow-on funding, according to Activate's website.

Activate officially named its Houston office in the Ion last year.

Charlie Childs, co-founder and CEO of Intero Biosystems, which won both the top-place finish and the largest total investment at this year's Rice Business Plan Competition, was named to the Activate Anywhere cohort. Read more about the Boston, New York, Berkley and Activate Anywhere cohorts here.

View All Listings